TipRanks on MSN13h
Disc Medicine price target raised to $132 from $99 at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Disc Medicine (IRON) to $132 from $99 and keeps an Overweight rating on ...
Hosted on MSN11mon
Disc Medicine (IRON) Down on Mixed Results From AURORA Study
Consequently, Disc Medicine will conduct an analysis of ... of bitopertin as a glycine transporter 1 and its effect on heme biosynthesis. EPP and XLP are rare, debilitating and potentially life ...
ETF Daily News6d
Disc Medicine, Inc. (NASDAQ:IRON) Shares Bought by Victory Capital Management Inc.
primarily heme biosynthesis and iron homeostasis. Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts ...
Disc Medicine (NASDAQ:IRON) Stock Price Expected to Rise, Scotiabank Analyst Says
Disc Medicine (NASDAQ:IRON – Get Free Report) had its target price boosted by investment analysts at Scotiabank from $73.00 to $75.00 in a note issued to investors on Monday,Benzinga reports. The firm ...